{'fraction_non_alphanumeric': 0.020202020202020204, 'fraction_numerical': 0.017316017316017316, 'mean_word_length': 5.087719298245614, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Protease inhibitors may be associated with premature births.


 The National Institutes of Health (NIH) announced that it has temporarily suspended enrollment of pregnant women into perinatal trials of protease inhibitors because protease inhibitors may increase the risk of premature births. Enrollment was halted for Pediatric AIDS Clinical Trials Group (PACTG) trials 353, 354, 358, and 386. The concerns are based on preliminary data, and women already taking protease inhibitors should continue to take them. Studies to date have included a very limited number of pregnant women, and it is unclear whether the premature births were due to the use of protease inhibitors or other factors.
